Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AF0150; AFO 150; Imagent; Imavist

Latest Information Update: 09 Dec 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IMCOR Pharmaceutical
  • Class Fluorocarbons; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 09 Dec 2004 IMCOR commenced a phase II study investigating alternative methods of administration for perflexane such as repeat dosing and infusion
  • 12 Feb 2004 Photogen Technologies is now called IMCOR Pharmaceutical
  • 22 Dec 2003 Perflexane has been licensed to Kyosei Pharmaceutical Co. Ltd. for radiology and cardiology indications in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top